Subtype
Prostate Neuroendocrine Neoplasm
CI-CAN-00001444Explore in graph →
Non-malignant8 active trials
Loading cancer entity…
Subtype
CI-CAN-00001444Explore in graph →
Clinical trials
12 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03582475 | Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or Prostate | active not recruiting | Phase 1 | 15 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Nov 12, 2025 | clinicaltrials |
| NCT06062745 | Pilot Study for Detection of PSMA-Low CRPC-NE Tumors With Fluciclovine PET/CT | recruiting | Phase 1 | 30 | Brigham and Women's HospitalOTHER | 1 | Nov 5, 2025 | clinicaltrials |
| NCT06094842 | Autologous T Cells Lentivirally Transduced to Express L1CAM-Specific Chimeric Antigen Receptors in Treating Patients With Locally Advanced and Unresectable or Metastatic Small Cell Neuroendocrine Prostate Cancer | withdrawn | Phase 1 | 0 | Fred Hutchinson Cancer CenterOTHER | 1 | Apr 1, 2025 | clinicaltrials |
Data updated 22 days agoSource updated Nov 12, 2025source: clinicaltrials
| NCT01505868 |
| Cabazitaxel With or Without Carboplatin in Treating Patients With Previously Treated Metastatic Castration-Resistant Prostate Cancer |
| completed |
| Phase 1 / Phase 2 |
| 170 |
| M.D. Anderson Cancer CenterOTHER |
| 1 |
| Jul 30, 2021 |
| clinicaltrials |